Array Biopharma Inc.

Novartis Ag

Loxo Oncology, Inc.

Intermune, Inc.

Genentech, Inc.

Weidong Liu

Paul Nichols

Peter J Stengel

Christoph Max Krell

Werner Heinz Pachinger

Daniel Zimmermann

Marian Misun

Daniel Andreas Niederer

Marie-Christine Wolf

Steven Wade Andrews

Gabrielle R Kolakowski

Adam Wade Cook

Tony P Tang

David A Moreno

Andrew T Metcalf

Charles Todd Eary

Stacey Spencer

Mike Welch

Katelyn Chando

Sylvie Asselin

Zack Crane

Yutong Jiang

Pierre Martin

Bin Wang

Timothy S Kercher

Scott D Seiwert

Lawrence M Blatt

Michael Lyon

April L Kennedy

Andreas Schumacher

C Todd Eary

Robert J Kaus

Tarek Sammakia

Zackary D Crane

Bradley Barnett

Joseph P Lyssikatos

Qian Zhao

Michelangelo Scalone

Shelley Allen

Francis Gosselin

Keith Lee Spencer

Sagar Raj Shakya

Chong Han

Daniel John Watson

Julie Marie Greschuk

D David Hennings

Paul J Nichols

Fredrik P Marmsäter

Brian C Baer

Keena Green

Bradley R Barnett

Brian Baer

Zackary Crane

In some embodiments, provided herein is a process for preparing a compound of Formula I or a pharmaceutically acceptable salt thereof, as disclosed herein.

Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbontrile

Provided is Compound (I) or a pharmaceutically acceptable salt thereof, which is an inhibitor of TrkA kinase and is useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation and inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, pelvic pain syndrome, diseases related to an imbalance of the regulation of bone remodeling, and diseases resulting from Connective Tissue Growth Factor aberrant signaling. 

1 -((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1H-pyrazol-5-yl)urea as a TrkA kinase inhibitor

The present invention relates to processes for preparing 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, processes for preparing crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, and intermediates useful therefore. Also provided herein are pharmaceutical compositions comprising this crystallized compound.

Preparation of and formulation comprising a MEK inhibitor

The invention provides processes of preparation thereof useful in the preparation of compounds that can be used as CHK1 inhibitors.

Process for preparing a compound

The present invention relates to processes for preparing 6-(4-bromo-2-fluorophenylamino)-7-fluoro -3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, processes for preparing crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, and intermediates useful therefore. Also provided herein are pharmaceutical compositions comprising this crystallized compound.

This invention provides compounds of Formula I wherein B, G, A, E, R, R, R, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.

N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases

The embodiments provide compounds of the general Formulae I through general Formula VIII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Macrocyclic inhibitors of hepatitis C virus replication

Growing community of inventors

Boulder, CO, United States of America

Weidong Liu